drugset / Trial / NCT07417696
Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease
Phase 4
Not yet recruiting
400 enrolled
Chinese Medical Association
First Affiliated Hospital, Sun Yat-Sen University · collabShenzhen University General Hospital · collabSixth Affiliated Hospital, Sun Yat-sen University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate whether the combination of palmitoleic acid with infliximab can improve intestinal mucosal healing in patients with Crohn's disease compared with infliximab alone.
Timeline
- Start
- 2026-04-01
- Primary completion
- 2029-03-31
- Completion
- 2029-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Infliximab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | palmitoleic acid | Small molecule | 720 mg | Oral |